Skip to main content

Table 1 Patient characteristics at baseline

From: Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy

  Number Percentage
Eyes/Patients 80/74  
Gender (male) 45 60.8%
Age (years) 68.9 ± 9.3  
Lens status (phakic) 69 86.3%
Mean baseline BCVA (letters) 49.7 ± 18.0  
Mean baseline CRT (μm) 695.1 ± 319.5  
PED 70 87.5%
Subretinal fluids 71 88.8%
Retinal/subretinal hemorrhage 25 31.3%
  1. BCVA best corrected visual acuity, CRT central retinal thickness, PED pigment epithelial detachment